ENROFLOXACIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

The global enrofloxacin market size is expected to witness potential gains in the future, and register a significant CAGR over the forecast period (2019 - 2027).

Market Overview

Enrofloxacin (ENR) is a fluoroquinolone antibiotic and a veterinary antibacterial agent. It is sold under the trade name Baytril by the Bayer Corporation. ENR is currently approved for treatment of individual pets and domestic animals in the U.S. by the U.S. Food and Drug Administration (FDA). ENR is effective against a several gram-positive and gram-negative bacteria such as Pseudomonas aeruginosa, Klebsiella, and E.coli. It is used for the treatment of infections of skin and soft tissue, urinary tract infections in dogs and cats, Chlamydophila felis infections in cats, and ulcerative colitis caused by Escherichia coli in dogs. Significant growth in the poultry sector is expected to have positive impact on the market growth of enrofloxacin over the forecast period.

Market Dynamics

Increasing use of ENR in treatment of infections caused by both Gram-negative and Gram-positive bacteria is expected to boost the market growth. ENR is administered to cattle by subcutaneous injection and to pigs by intramuscular injection. It is administered orally to cattle, pigs, turkey, and chickens, for the treatment of infections of the respiratory and alimentary tract.

However, in rare instances, use of ENR in cats has been linked with retinal toxicity. The drug cannot be used in pets that are allergic to it. ENR is also associated with some side effects such as vomiting, diarrhea, and lack of appetite. Moreover, effective in September 2005, enrofloxacin was withdrawn from use in the U.S. poultry farms. These factors are expected to hinder growth of the enrofloxacin market over the forecast period.

Increasing trend of adopting pets is expected to offer lucrative opportunities for market players to enhance their market share.    

Market Outlook

Asia Pacific is expected to hold dominant position in the enrofloxacin market over the forecast period. Factors such as growing population and high demand for poultry meat are expected to impact the market growth. Moreover, significant growth in the pet industry in China is also expected to contribute to the market growth in Asia Pacific. Restrictions on the use of ENR in the U.S. is expected to adversely affect growth of the market in North America.

Key Players

Some of the major players operating in the global enrofloxacin market include, Bayer Corporation, KRKA d.d., Novo mesto, Pro Zoon, Chanelle Pharmaceuticals, VetMedic, and VM Pharma.